AIM
ACAD icon

Aigen Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Aigen Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,030
Closed -$277K – 692
2024
Q2 		$277K Sell
17,030
-33,478
-66% -$540K 0.05% 506
2024
Q1 		$934K Sell
50,508
-2,013
-4% -$49.9K 0.2% 153
2023
Q4 		$1.64M Buy
52,521
+37,455
+249% +$894K 0.29% 84
2023
Q3 		$314K Buy
+15,066
New +$409K 0.06% 510
2020
Q4 		– Sell
-20,360
Closed -$840K – 746
2020
Q3 		$840K Buy
+20,360
New +$879K 0.11% 299

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return